* Treatment recommendations are made for high-risk patients only, evidence for low- or intermediate-risk ET or PV management is unavailable.

† Not currently licensed for this indication.

‡ Current British Guidelines recommend regular monitoring of patients treated with Anagrelide for the development of fibrosis.⁴¹